The short version of thymosin beta-4 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-01. Anything still debated is marked as such rather than presented as settled.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
== Research == Liposomal medicine research for cancer therapy has increased over the years as an alternative to conventional cancer treatment. There is an interest in liposomal medicine because it features targeted drug delivery while mitigating the damage to healthy cells and tissues. One of the combination products under liposome therapy that is being researched for cancer therapy applications is immunoliposome therapy. Other research areas in liposome combination therapy include photodynamic therapy, photothermal agents, radiotherapy, and gas therapy agents. A immunoliposome therapy clinical study that was completed was conducted by the Swiss Group for Clinical Cancer Research from 2006 to 2009. The study was a phase II clinical trial that looked at the combination of commercially sold Doxorubicin with bevacizumab, a monoclonal antibody that blocks tumor growth. The therapy was used to treat patients with locally recurrent or metastatic breast cancer. Out of the 43 patients, 16 had grade 3 palmar-plantar erythrodysesthesia, one had grade 3 mucositis, and one severe cardiotoxicity, according to the study. As a result, the combination therapy demonstrated higher than anticipated toxicity while only having modest therapeutic effect. These results concluded that, although immunoliposome therapy has promise, there is still more research needed before translating into commercial products.
Sigma RBI produces specialized products for use in the field of cell signaling and neuroscience. Their offerings range from standard biochemical reagents to specialized research tools, including ligands for receptors and ion channels, enzyme inhibitors, phosphospecific antibodies, key signal transduction enzymes, and assay kits for cell signaling.
== Tissue distribution == COL21A1 is expressed in a broad range of tissues, including skin, trachea, testis, uterus, placenta, lymph node, stomach and the walls of blood vessels, generally overlapping the distribution of type I collagen. Among these, relative expression is highest in lymph node, jejunum, pancreas, stomach, trachea, testis, uterus and placenta; moderate levels are found in brain, colon, lung, prostate, spinal cord, salivary gland and vascular smooth-muscle cells; and expression is weak in heart, liver, kidney, bone marrow, spleen and thymus. COL21A1 expression is developmentally regulated, being higher at fetal stages than in the corresponding adult tissues. In a comparison of matched human tissues, COL21A1 transcripts were approximately 2.7-, 22- and 30-fold more abundant in fetal brain, heart and liver, respectively, than in their adult counterparts, suggesting a role in developmental processes. In cultured aortic smooth-muscle cells, expression of COL21A1 is stimulated by platelet-derived growth factor (PDGF). Its presence in the walls of blood vessels, where it is produced by smooth-muscle cells, was noted in the original characterization of the gene. Type XXI collagen is also expressed in human skin, where it is a low-abundance component of the dermal extracellular matrix, as detected by quantitative proteomics of healthy skin. In a time-resolved proteomic atlas of the developing skin dermis, type XXI collagen was among the fibril-associated collagens whose abundance declined progressively with age over the human lifespan.
As the elastic walls of the vagina stretch or contract, with support from the pelvic muscles, to wrap around the inserted penis (or other object), this creates friction for the penis and helps to cause a man to experience orgasm and ejaculation, which in turn enables fertilization. An area in the vagina that may be an erogenous zone is the G-spot. It is typically defined as being located at the anterior wall of the vagina, a couple or few inches in from the entrance, and some women experience intense pleasure, and sometimes an orgasm, if this area is stimulated during sexual activity. A G-spot orgasm may be responsible for female ejaculation, leading some doctors and researchers to believe that G-spot pleasure comes from the Skene's glands, a female homologue of the prostate, rather than any particular spot on the vaginal wall; other researchers consider the connection between the Skene's glands and the G-spot area to be weak. The G-spot's existence (and existence as a distinct structure) is still under dispute because reports of its location can vary from woman to woman, it appears to be nonexistent in some women, and it is hypothesized to be an extension of the clitoris and therefore the reason for orgasms experienced vaginally.
Isotope masses from: M. Wang; G. Audi; A. H. Wapstra; F. G. Kondev; M. MacCormick; X. Xu; et al. (2012). "The AME2012 atomic mass evaluation (II). Tables, graphs and references" (PDF). Chinese Physics C. 36 (12): 1603–2014. Bibcode:2012ChPhC..36....3M. doi:10.1088/1674-1137/36/12/003. hdl:11858/00-001M-0000-0010-23E8-5. S2CID 250839471. Archived from the original (PDF) on 2013-09-28. Retrieved 2013-07-03. Audi, Georges; Bersillon, Olivier; Blachot, Jean; Wapstra, Aaldert Hendrik (2003), "The NUBASE evaluation of nuclear and decay properties", Nuclear Physics A, 729: 3–128, Bibcode:2003NuPhA.729....3A, doi:10.1016/j.nuclphysa.2003.11.001 Half-life, spin, and isomer data selected from the following sources. Audi, Georges; Bersillon, Olivier; Blachot, Jean; Wapstra, Aaldert Hendrik (2003), "The NUBASE evaluation of nuclear and decay properties", Nuclear Physics A, 729: 3–128, Bibcode:2003NuPhA.729....3A, doi:10.1016/j.nuclphysa.2003.11.001 National Nuclear Data Center. "NuDat 3.0 database". Brookhaven National Laboratory. Holden, Norman E. (2004). "11. Table of the Isotopes". In Lide, David R. (ed.). CRC Handbook of Chemistry and Physics (85th ed.). Boca Raton, Florida: CRC Press. ISBN 978-0-8493-0485-9.
Sources: en.wikipedia.org
Within the United States, the Patient Protection and Affordable Care Act of 2010 created an abbreviated approval pathway for biological products shown to be biosimilar to, or interchangeable with, an FDA-licensed reference biological product. Researchers are optimistic that the introduction of biosimilars will reduce medical expenses to patients and the healthcare system.
(2026) report the discovery of a new site (Emiliano Aguirre Korongo) at Olduvai Gorge (Tanzania) preserving proboscidean remains with bone modifications interpreted as the authors as evidence of butchery assisted by stone tools, and interpret the fossil record of megafaunal bone modifications at Olduvai Gorge as consistent with more frequent and widespread megafaunal butchery after 1.8 million years ago, roughly coinciding with the replacement of Oldowan industries by Acheulean ones. Evidence from the study of burnt bones of small mammals from the Acheulean deposits from the Wonderwerk Cave (South Africa), indicative of repeated use of fire by Early Pleistocene hominins, is presented by Marin-Monfort et al. (2026). Evidence from the study of an approximately 1.6 million years old assemblage of associated hominin fossils and butchered fauna from the KBS Member of the Koobi Fora Formation, indicative of consistent foraging strategies of early Homo across time and in different environments, is presented by Forrest et al. (2026). Campo-Gómez et al. (2026) determine prey carrying capacity and total biomass of the Early Pleistocene large mammal community available to hominins from the Sima del Elefante site (Spain), interpreted as capable of sustaining hominin groups of low density. Wang et al. (2026) study the morphology of lumbar vertebrae of immature individuals of Homo erectus and Australopithecus sediba from Georgia, Kenya and South Africa, reporting evidence of establishment of vertebral traits related to bipedal locomotion early in hominin ontogeny and evolution.
The hydrocarbon-generating potential and thermal maturity of petroleum source rocks are commonly evaluated using Rock-Eval pyrolysis and vitrinite reflectance measurements, which provide quantitative indicators of organic matter type, maturation level, and the likelihood of oil or gas generation. Catagenesis was pyrolytic despite the fact that it happened at relatively low temperatures (when compared to commercial pyrolysis plants) of 60 to several hundred °C. Pyrolysis was possible because of the long reaction times involved. Heat for catagenesis came from the decomposition of radioactive materials of the crust, especially 40K, 232Th, 235U and 238U. The heat varied with geothermal gradient and was typically 10–30 °C per km of depth from the Earth's surface. Unusual magma intrusions, however, could have created greater localized heating.
=== IR sources === FTIR spectrometers are mostly used for measurements in the mid and near IR regions. For the mid-IR region, 2−25 μm (5,000–400 cm−1), the most common source is a silicon carbide (SiC) element heated to about 1,200 K (930 °C; 1,700 °F) (Globar). The output is similar to a blackbody. Shorter wavelengths of the near-IR, 1−2.5 μm (10,000–4,000 cm−1), require a higher temperature source, typically a tungsten-halogen lamp. The long wavelength output of these is limited to about 5 μm (2,000 cm−1) by the absorption of the quartz envelope. For the far-IR, especially at wavelengths beyond 50 μm (200 cm−1) a mercury discharge lamp gives higher output than a thermal source.
However, for such applications actinides are less suitable than lighter radioisotopes as the critical mass is orders of magnitude below the mass needed to produce such amounts of power. As Sr-90, Cs-137 and other lighter radionuclides cannot maintain a nuclear chain reaction under any circumstances, RTGs of arbitrary size and power could be assembled from them if enough material can be produced. In general, however, potential applications for such large-scale RTGs are more the domain of small modular reactors, microreactors or non-nuclear power sources.
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.